Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept
about
Influence of TNF and IL6 gene polymorphisms on the severity of cytopenias in Argentine patients with myelodysplastic syndromes.Targeting DNA methylation for epigenetic therapy.Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia.Value of infliximab (Remicade®) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia GroupDigging deep into "dirty" drugs - modulation of the methylation machinery.Epigenetic drug discovery: targeting DNA methyltransferases.Combination strategies in myelodysplastic syndromes.Emerging immunosuppressive drugs in myelodysplastic syndromes.5-Azacytidine for the treatment of myelodysplastic syndromes.Chronic myelomonocytic leukemia prognostic classification and management: evidence base and current practice.Stopping higher-risk myelodysplastic syndrome in its tracks.New Insights into the Pathogenesis of MDS and the rational therapeutic opportunities.Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia.Myelodysplastic Syndromes in the Elderly: Treatment Options and Personalized Management.Tumor necrosis factor restricts hematopoietic stem cell activity in mice: involvement of two distinct receptorsAllogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire.Reply to “Infliximab therapy in hematologic malignancies: handle with care” 2012;97(8):e26.The bone-marrow niche in MDS and MGUS: implications for AML and MM.Leukaemic transformation in patients with haematological disease receiving tumour necrosis factor inhibitors.
P2860
Q33442617-20A18FA2-6CE3-4654-A9B0-DA432B1553A6Q34258037-3017F279-5B4E-45D9-BC48-ED90B5A43F2CQ34273735-91D742EA-97C4-47F4-AFC5-C54E8E2C6F6AQ35944694-ACAC602B-A258-4F86-BE41-B2287221B22DQ36523796-3BB4305F-B0A8-4B24-B009-24F823D9F22CQ37941536-F0F70CE4-B963-4BF1-91A8-4BBDE12ED79FQ37973280-72B3F617-5DEF-4115-8DE4-ACE394846CC6Q38060835-B3FA36A9-5810-41B5-BC1A-720204E0CFEDQ38102062-63E0DAD2-4E70-475E-9A93-DFE192B347F5Q38241774-B66FFF0F-FE81-445A-84E5-758EF9AB7081Q38248180-B057BBDB-83D3-45E0-86E8-0F48B76CFE5CQ38687894-17E0E688-885D-487F-BE11-A165F164386FQ38984169-54EF1CB9-47E7-47C8-B506-A95239F2F1BCQ40420210-C23C88C3-CDE9-409E-92D0-E2ECF945FDF7Q42018205-3961DD5A-BE56-4931-A7B1-9A792AD0628DQ46373480-1917E38F-D1CC-42AC-8B15-B6894DC6BAA2Q46488130-F7740B84-2FEA-4467-A227-FF902E0FF993Q50114615-41C9D2D6-2E74-454B-BBC8-C2C0291427C3Q53131035-87B7A095-EB67-45D8-8B01-89AA6DE4CB2A
P2860
Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept
@ast
Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept
@en
type
label
Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept
@ast
Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept
@en
prefLabel
Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept
@ast
Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept
@en
P2093
P2860
P1476
Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept
@en
P2093
Aravind Ramakrishnan
Bart L Scott
Elihu H Estey
Pamela S Becker
Steve Petersdorf
P2860
P304
P356
10.1111/J.1365-2141.2009.08061.X
P407
P577
2010-01-07T00:00:00Z